EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate‐polyglutamate 3

Jean Escal iD, Marion Poudret, Sophie Hodin, Tiphany Neel, Irina Coman, Hervé Locrelle, Adamah Amouzougan, Thierry Thomas, Xavier Delavenne, Hubert Marotte

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.13050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Jean Escal und 9 weiteren Autor:innen. Beteiligte Einrichtung: CHU Saint-Etienne, Laboratoire de Pharmacologie et Toxicologie, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Université Jean Monnet Saint-Étienne, S…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Methotrexate, Erythrocytes, Polyglutamic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nordic Pharma Group, Nordic Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methotrexate (MTX) is the first‐line treatment for Rheumatoid Arthritis (RA), yet 30%–50% of RA patients develop resistance to MTX, which can manifest several years after treatment initiation.

Objective

This study investigates the relationship between erythrocyte methotrexate polyglutamates (MTX‐PGs) subtype concentrations and clinical disease activity in RA patients undergoing long‐term MTX treatment.

Methods

In this cross‐sectional study, patients on a stable dose of subcutaneous MTX for several years were included. The study protocol was registered in the European Medicines Agency's clinical trials register (n°2017‐004348‐39). Patients were classified as either in clinical remission (DAS28 3.2). Erythrocyte MTX‐PGs concentrations were measured using liquid chromatography coupled with mass spectrometry. Multivariate logistic regression analysis assessed the probability of remission status based on MTX‐PG3 concentrations.

Results

The study included 34 patients with active RA and 25 in remission. The remission group had a median MTX treatment duration of 6.4 years compared to 2.6 years for the active group ( p = 0.001). Patients in remission had a longer median disease duration ( p = 0.02) and a lower Body Mass Index (BMI) ( p = 0.03) than those with active RA. A positive correlation was found between remission status and high MTX‐PG3 concentrations in patients with a BMI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidMethotrexateErythrocytesPolyglutamic AcidAntirheumatic AgentsHumansMaleFemaleMiddle AgedCross-Sectional StudiesAgedAdultTreatment OutcomeRemission Induction

Stichwörter der Autor:innen

biomarkerliquid chromatography‐mass spectrometrymethotrexate resistancemethotrexate‐polyglutamaterheumatoid arthritis

Substanzen

MethotrexatePolyglutamic AcidAntirheumatic Agentsmethotrexate polyglutamate

Autor:innen und Institutionen

  • CHU Saint-Etienne, Laboratoire de Pharmacologie et Toxicologie, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Université Jean Monnet Saint-Étienne, Saint-Etienne, France.
  • CHU Saint-Étienne, Service de Rhumatologie, Saint-Etienne, France.
  • Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Université Jean Monnet Saint-Étienne, Saint-Etienne, France.
  • CHU Saint-Étienne, Service de Rhumatologie, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Université Jean Monnet Saint-Étienne, Saint-Etienne, France.

ORCID-Profile: Jean Escal

Förderung

  • Nordic Pharma Group
  • Nordic Pharma

Zitieren

APA

Escal, J., Poudret, M., Hodin, S., Neel, T., Coman, I., Locrelle, H., Amouzougan, A., Thomas, T., Delavenne, X., & Marotte, H. (2025). Long‐term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate‐polyglutamate 3. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.13050

Vancouver

Escal J, Poudret M, Hodin S, Neel T, Coman I, Locrelle H, et al. Long‐term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate‐polyglutamate 3. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.13050

BibTeX
@article{Escal2025,
  author = {Escal, Jean and Poudret, Marion and Hodin, Sophie and Neel, Tiphany and Coman, Irina and Locrelle, Hervé and Amouzougan, Adamah and Thomas, Thierry and Delavenne, Xavier and Marotte, Hubert},
  title = {Long‐term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate‐polyglutamate 3},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.13050}
}
Kostenlos starten →